Hohla, Florian and Buchholz, Stefan and Schally, Andrew V. and Krishan, Awtar and Rick, Ferenc G. and Szalontay, Luca and Papadia, Andrea and Halmos, Gabor and Koster, Frank and Aigner, Elmar and Datz, Christian and Seitz, Stephan (2010) Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. CANCER LETTERS, 294 (1). pp. 35-42. ISSN 0304-3835, 1872-7980
Full text not available from this repository. (Request a copy)Abstract
The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29. HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | HORMONE-RELEASING-HORMONE; CANCER; EXPRESSION; AN-238; INTERNALIZATION; GLYCOPROTEIN; CHEMOTHERAPY; ENDOMETRIAL; ANTAGONISTS; RECEPTORS; AN-162; Targeted therapy; Colon cancer; Somatostatin; Doxorubicin |
Subjects: | 600 Technology > 610 Medical sciences Medicine |
Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
Depositing User: | Dr. Gernot Deinzer |
Date Deposited: | 20 Jul 2020 07:12 |
Last Modified: | 20 Jul 2020 07:12 |
URI: | https://pred.uni-regensburg.de/id/eprint/24355 |
Actions (login required)
View Item |